United States-based global pharmaceutical company MSD said on Monday that China's National Medical Products Administration has approved the use of multiple new indications of Gardasil®9, its ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

Merck is in hot water after a class action lawsuit alleged securities fraud over its Gardasil revenue forecasts in China. The lawsuit claims Merck misled investors about its ability to achieve $11 ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Merck's expected revenue of $11 billion from sales of Gardasil by 2030. Defendants' ...

Bernstein Liebhard LLP reminds Merck investors of an April 14, 2025 deadline to join a securities fraud class action lawsuit. The case alleges Merck misrepresented the demand for its Gardasil vaccine ...

GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.

Gardasil 9 is the only HPV vaccine used in the U.S., and it’s also one of the only vaccines on the market that actually prevents cancer. That’s because HPV is behind nearly all cervical cancer cases ...